Ahmedabad-based holding company running pharmaceutical (API, formulations, effervescent), molecular-diagnostics and scientific/broadcast-instruments businesses through subsidiaries and joint ventures
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 |
| Reserves | -32 | -3 | 43 | 54 | 60 | 63 | 71 | 82 |
| Borrowings | 31 | 28 | 27 | 45 | 46 | 51 | 47 | 57 |
| Other Liabilities | 111 | 108 | 84 | 70 | 67 | 79 | 66 | 65 |
| Total Liabilities | 186 | 210 | 231 | 246 | 250 | 270 | 260 | 280 |
| AssetsFixed Assets | 57 | 57 | 58 | 85 | 88 | 87 | 87 | 89 |
| CWIP | 0 | 1 | 12 | 4 | 0 | 0 | 0 | 4 |
| Investments | 18 | 27 | 33 | 32 | 29 | 32 | 32 | 32 |
| Other Assets | 110 | 125 | 128 | 125 | 133 | 151 | 141 | 155 |
| Total Assets | 186 | 210 | 231 | 246 | 250 | 270 | 260 | 280 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 19 | -7 | -2 | 11 | 6 | 9 | -18 | 13 |
| Cash from Investing | -9 | 17 | 10 | 5 | -17 | -5 | 13 | -10 |
| Cash from Financing | -6 | -14 | -6 | -19 | 9 | -3 | -2 | -2 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 9 | -10 | 7 | 16 | -15 | 6 | -20 | 7 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
500009 · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.